Biotech Premarket Movers: BioCryst, Sangamo, Cempra


Shares of BioCryst Pharmaceuticals were down 22.6% in premarket trading to $4.25. The Research Triangle Park, North Carolina-based company on Monday reported a fourth-quarter net loss of 6 cents per share, compared with a net loss of 25 cents per share in the year-ago period.



from Biotech News